Delaware
(State or other jurisdiction of incorporation or organization)
|
001-37367
(Commission
File Number)
|
06-1614015
(I.R.S. Employer
Identification Number) |
(d) |
Exhibits.
|
99.1 |
Press Release, dated April 26, 2017, issued by OpGen, Inc.
|
OpGen, Inc. | |||
Date: April 26, 2017
|
By:
|
/s/ Timothy C. Dec | |
Timothy C. Dec | |||
Chief Financial Officer | |||
Exhibit No.
|
Document
|
99.1
|
Press Release, dated April 26, 2017, issued by OpGen, Inc.
|
· |
Revenue: Total revenue for the three months ended March 31, 2017 was $0.8 million compared with $1.1 million for the three months ended March 31, 2016.
|
· |
Operating Expenses: Operating expenses for the three months ended March 31, 2017 were $5.7 million compared with $5.6 million for the three months ended March 31, 2016.
|
· |
Net Loss: Net loss for the three months ended March 31, 2017 was $5.0 million compared with $4.5 million for the three months ended March 31, 2016.
|
· |
Cash Position: Cash and cash equivalents were $1.7 million as of March 31, 2017 compared with $4.1 million as of December 31, 2016.
|
· |
Moved our Acuitas Rapid Test into full development with a goal of implementing the technology for external research use in the second half of the year.
|
· |
Continued to build and expand our Acuitas Lighthouse Knowledgebase by completing genotype/phenotype testing for 4,000 clinical isolates from the Merck SMART Surveillance Network and other collaborator clinical sites.
|
· |
Presented rapid Acuitas genetic test data at Advances in Genome Biology and Technology (AGBT) Meeting.
|
· |
Presentation of posters highlighting ability of our Acuitas technology to rapidly predict antibiotic resistance and detect outbreaks with drug resistance gene profiles at ECCMID 2017.
|
· |
Raised $2.1 million of net proceeds through the sale of common stock under our at the market offering.
|
·
|
Genomic and antibiotic resistance testing of 10,000 multidrug resistant organisms to support initial development of the first Acuitas Rapid Test kits and deployment of the Acuitas Lighthouse Knowledgebase.
|
·
|
Completion of initial Acuitas Rapid Test development and Acuitas Lighthouse genotype/phenotype predictive algorithms and clinical performance verification.
|
·
|
Announcement of in vitro diagnostic instrument supply and cooperation agreement to support global commercialization of the Acuitas Rapid Test.
|
·
|
Establishment of distribution and partnering relationships to support commercialization of the Acuitas Rapid Test and the Acuitas Lighthouse Knowledgebase in international markets.
|
·
|
Establishment of Acuitas Rapid Test early access and performance verification programs to support regulatory approval clinical trials and publications.
|
·
|
Presentation of Acuitas Rapid Test and performance data at medical meetings and in peer reviewed journals.
|
March 31, 2017
|
December 31, 2016
|
|||||||
Assets
|
||||||||
Current assets
|
||||||||
Cash and cash equivalents
|
$
|
1,670,311
|
$
|
4,117,324
|
||||
Accounts receivable, net
|
379,246
|
542,420
|
||||||
Inventory, net
|
642,961
|
692,368
|
||||||
Prepaid expenses and other current assets
|
267,971
|
329,646
|
||||||
Total current assets
|
2,960,489
|
5,681,758
|
||||||
Property and equipment, net
|
743,521
|
800,723
|
||||||
Goodwill
|
600,814
|
600,814
|
||||||
Intangible assets, net
|
1,554,044
|
1,620,998
|
||||||
Other noncurrent assets
|
298,081
|
279,752
|
||||||
Total assets
|
$
|
6,156,949
|
$
|
8,984,045
|
||||
Liabilities and Stockholders' Equity
|
||||||||
Current liabilities
|
||||||||
Accounts payable
|
$
|
2,017,202
|
$
|
2,232,563
|
||||
Accrued compensation and benefits
|
1,019,962
|
578,480
|
||||||
Accrued liabilities
|
883,105
|
1,215,283
|
||||||
Deferred revenue
|
31,233
|
37,397
|
||||||
Short-term notes payable
|
998,958
|
1,023,815
|
||||||
Current maturities of long-term capital lease obligation
|
170,297
|
184,399
|
||||||
Total current liabilities
|
5,120,757
|
5,271,937
|
||||||
Deferred rent
|
374,194
|
398,084
|
||||||
Long-term capital lease obligation and other noncurrent liabilities
|
107,940
|
146,543
|
||||||
Total liabilities
|
5,602,891
|
5,816,564
|
||||||
Stockholders' equity
|
||||||||
Common stock, $0.01 par value; 200,000,000 shares authorized; 27,377,490 and 25,304,270 shares issued and outstanding at March 31, 2017 and December 31, 2016, respectively
|
273,775
|
253,042
|
||||||
Preferred stock, $0.01 par value; 10,000,000 shares authorized; none issued and outstanding at March 31, 2017 and December 31, 2016, respectively
|
—
|
—
|
||||||
Additional paid-in capital
|
138,546,915
|
136,199,382
|
||||||
Accumulated other comprehensive income
|
2,419
|
6,176
|
||||||
Accumulated deficit
|
(138,269,051
|
)
|
(133,291,119
|
)
|
||||
Total stockholders' equity
|
554,058
|
3,167,481
|
||||||
Total liabilities and stockholders' equity
|
$
|
6,156,949
|
$
|
8,984,045
|
Three Months Ended March 31,
|
||||||||
2017
|
2016
|
|||||||
Revenue
|
||||||||
Product sales
|
$
|
734,502
|
$
|
947,219
|
||||
Laboratory services
|
16,105
|
129,420
|
||||||
Collaboration revenue
|
21,164
|
—
|
||||||
Total revenue
|
771,771
|
1,076,639
|
||||||
Operating expenses
|
||||||||
Cost of products sold
|
424,950
|
345,967
|
||||||
Cost of services
|
100,233
|
315,709
|
||||||
Research and development
|
2,122,515
|
1,953,429
|
||||||
General and administrative
|
1,969,216
|
1,538,046
|
||||||
Sales and marketing
|
1,105,586
|
1,399,435
|
||||||
Total operating expenses
|
5,722,500
|
5,552,586
|
||||||
Operating loss
|
(4,950,729
|
)
|
(4,475,947
|
)
|
||||
Other expense
|
||||||||
Interest and other income
|
21
|
173
|
||||||
Interest expense
|
(29,844
|
)
|
(41,734
|
)
|
||||
Foreign currency transaction gains
|
2,620
|
11,328
|
||||||
Total other expense
|
(27,203
|
)
|
(30,233
|
)
|
||||
Loss before income taxes
|
(4,977,932
|
)
|
(4,506,180
|
)
|
||||
Provision for income taxes
|
—
|
—
|
||||||
Net loss
|
(4,977,932
|
)
|
(4,506,180
|
)
|
||||
Preferred stock dividends and beneficial conversion
|
—
|
—
|
||||||
Net loss available to common stockholders
|
$
|
(4,977,932
|
)
|
$
|
(4,506,180
|
)
|
||
Net loss per common share - basic and diluted
|
$
|
(0.19
|
)
|
$
|
(0.36
|
)
|
||
Weighted average shares outstanding - basic and diluted
|
26,079,461
|
12,568,941
|
||||||
Net loss
|
$
|
(4,977,932
|
)
|
$
|
(4,506,180
|
)
|
||
Other comprehensive loss - foreign currency translation
|
(3,757
|
)
|
(1,112
|
)
|
||||
Comprehensive loss
|
$
|
(4,981,689
|
)
|
$
|
(4,507,292
|
)
|